The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4740-4742

  Bell, Ian M ^a   Bednar, Rodney A ^a   Corcoran, Halea A ^a   Fay, John F ^a   Gallicchio, Steven N ^a   Johnston, Victor K ^a   Hershey, James C ^a   Miller Stein, Cynthia M ^a   Moore, Eric L ^a   Mosser, Scott D ^a   Roller, Shane A ^a   Salvatore, Christopher A ^a   Theberge, Cory R ^a   Wong, Bradley K ^a   Blair Zartman, C ^a   Kane, Stefanie A ^a   Williams, Theresa M ^a   Graham, Samuel L ^a   Vacca, Joseph P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CGRP; CGRP receptor antagonists; Migraine; Orally bioavailable

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; INDOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; MONKEY; NONHUMAN; RAT; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; DOGS; HAPLORHINI; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; RATS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SPIRO COMPOUNDS;

EID: 67651102827     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.057     Document Type: Article

References (16)

1. Goadsby P.J., Lipton R.B., and Ferrari M.D.N. Engl. J. Med. 346 (2002) 257
2. Silberstein S.D. Lancet 363 (2004) 381
3. Goadsby P.J. Drugs 65 (2005) 2557
4. Olesen J., Diener H.-C., Husstedt I.W., Goadsby P.J., Hall D., Meier U., Pollentier S., and Lesko L.M.N. Engl. J. Med. 350 (2004) 1104
5. Paone D.V., Shaw A.W., Nguyen D.N., Burgey C.S., Deng J.Z., Kane S.A., Koblan K.S., Salvatore C.A., Mosser S.D., Johnston V.K., Wong B.K., Miller-Stein C.M., Hershey J.C., Graham S.L., Vacca J.P., and Williams T.M.J. Med. Chem. 50 (2007) 5564
6. Salvatore C.A., Hershey J.C., Corcoran H.A., Fay J.F., Johnston V.K., Moore E.L., Mosser S.D., Burgey C.S., Paone D.V., Shaw A.W., Graham S.L., Vacca J.P., Williams T.M., Koblan K.S., and Kane S.A.J. Pharmacol. Exp. Ther. 324 (2008) 416
7. Ho T.W., Mannix L., Fan X., Assaid C., Furtek C., Jones C., Lines C., and Rapoport A. Neurology 70 (2008) 1304
8. Ho T.W., Ferrari M.D., Dodick D.W., Galet V., Kost J., Fan X., Leibensberger H., Froman S., Assaid C., Lines C., Koppen H., and Winner P.K. Lancet 372 (2008) 2115
9. Bell I.M., Bednar R.A., Fay J.F., Gallicchio S.N., Hochman J.H., McMasters D.R., Miller-Stein C., Moore E.L., Mosser S.D., Pudvah N.T., Quigley A.G., Salvatore C.A., Stump C.A., Theberge C.R., Wong B.K., Zartman C.B., Zhang X.-F., Kane S.A., Graham S.L., Vacca J.P., and Williams T.M. Bioorg. Med. Chem. Lett. 16 (2006) 6165
10. Stump C.A., Bell I.M., Bednar R.A., Bruno J.G., Fay J.F., Gallicchio S.N., Johnston V.K., Moore E.L., Mosser S.D., Quigley A.G., Salvatore C.A., Theberge C.R., Zartman C.B., Zhang X.-F., Kane S.A., Graham S.L., Vacca J.P., and Williams T.M. Bioorg. Med. Chem. Lett. 19 (2009) 214
11. Clark D.E.J. Pharm. Sci. 88 (1999) 807
12. Hershey J.C., Corcoran H.A., Baskin E.P., Salvatore C.A., Mosser S., Williams T.M., Koblan K.S., Hargreaves R.J., and Kane S.A. Regul. Pept. 127 (2005) 71
13. Sinclair S.R., Kane S.A., Xiao A., Willson K.J., Xu Y., Hickey L., Palcza J., deLepeleire I., Vanmolkot F., de Hoon J., and Murphy M.G. Headache 47 (2007) 811
14. Compound 5 was administered intravenously using a dose-escalating protocol similar to that described for MK-0974 (telcagepant) in Ref. 6.
15. 1H NMR, HPLC, and HRMS. Additional synthetic details are provided in: Bell, I. M.; Gallicchio, S. N.; Stump, C. A.; Theberge, C. R.; Vacca, J. P.; Zartman, C. B.; Zhang, X.-F. WO 2006/031491.
16. Downie I.M., Earle M.J., Heaney H., and Shuhaibar K.F. Tetrahedron 49 (1993) 4015